"Induction and Rejection Therapy"

This lecture covers "part 1" of Immunosuppression pharmacokinetics & therapeutic drug monitoring ("Induction/Rejection Therapy").

Use the markers on the video timeline to quickly navigate to important points in the video outlined below:
- Chapter 1: Introduction [0:37]
- Chapter 2: Available induction agents [2:39]
- Section A) Basiliximab overview [4:05]
- Section B) ATG preparations overview [7:42]
- Section C) Alemtuzumab overview [15:35]
- Section D) Corticosteroid overview [19:32]
- Chapter 3: Economic impact of induction [21:58]
- Chapter 4: Management of rejection overview [23:15]
- Section A) Acute cellular rejection therapies [24:17]
- Section B) Antibody-mediated rejection therapies [26:27]
- i) IVIG overview [28:14]
- ii) Rituximab overview [32:14]
- iii) Proteasome inhibitor overview [36:17]
- iv) Eculizumab overview [40:51]
- v) Impact of plasmapheresis on AMR treatment [43:46]
- vi) Economic Impact of AMR treatment [45:02]
- Chapter 5: Conclusion [45:46]

Steve Gabardi PharmD, BCPS, FAST, FCCP

Appearances